Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer

William W. Tseng, Adriana Deganutti, May N. Chen, Romaine E. Saxton, Carson D. Liu, G. Chandler, M. Jaffe, T. Brentnall, K. G. Billingsley

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Abstract

Recent studies indicate that cyclooxygenase-2 (COX-2) is overexpressed in pancreatic adenocarcinoma and may play a critical role in this rapidly progressing form of cancer. A human pancreatic adenocarcinoma cell line, Mia PaCa-2, was incubated for 18 hours with 5 μmol/L of rofecoxib (Vioxx), a selective COX-2 inhibitor. Total RNA was isolated and gene expression analyzed by DNA microarray chips. In a separate experiment, athymic mice were orthotopically injected with 7.5 × 105 Mia PaCa-2 cells through a minilaparotomy. After 1 month, laparotomy was repeated to measure tumor size, and mice were randomized to receive reformulated rodent chow containing either 12.5 mg/kg/day of rofecoxib or no drug for 21 days. Tumor growth was assessed by comparing volume before and after treatment. In vitro, rofecoxib decreased gene expression of cyclin D1/PRAD1, a key component of cell cycle progression, while increasing expression of several cell cycle arrest genes, including p21/WAF1, p33/ING, GADD34, and GADD45 (P < 0.05). In vivo, tumor growth was significantly reduced in treated vs. control mice (P < 0.05). No systemic toxicity was observed in mice receiving rofecoxib. These data suggest that rofecoxib slows the growth of human pancreatic cancer through changes in gene expression that favor cell cycle arrest.

Original languageEnglish (US)
Pages (from-to)838-844
Number of pages7
JournalJournal of Gastrointestinal Surgery
Volume6
Issue number6
DOIs
StatePublished - 2002
Externally publishedYes

Keywords

  • Cell cycle
  • Cyclooxygenase-2
  • Microarray
  • Pancreas cancer
  • Rofecoxib

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer'. Together they form a unique fingerprint.

Cite this